A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Clinical trial NCT05418972 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05418972
Sponsor: Melanoma Institute Australia
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stage II Melanoma

Start date: 2023-08-14
Primary completion: 2025-12-11
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.